Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. (Q52046676)

20 April 2018

title

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. (English)

1 reference

20 April 2018

1 reference

7

Rapoport SI

1 reference

20 April 2018

Mark B Schapiro

6

object named as

Schapiro MB

1 reference

20 April 2018

author name string

Asthana S

1

1 reference

20 April 2018

Greig NH

2

1 reference

20 April 2018

Holloway HW

3

1 reference

20 April 2018

Raffaele KC

4

1 reference

20 April 2018

Berardi A

5

1 reference

20 April 2018

Soncrant TT

8

1 reference

20 April 2018

language of work or name

English

0 references

publication date

1 September 1996

1 reference

20 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

20 April 2018

volume

60

1 reference

20 April 2018

issue

3

1 reference

20 April 2018

page(s)

276-282

1 reference

20 April 2018

Human memory and the cholinergic system. A relationship to aging?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Multiple-dose arecoline infusions in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Induction of depression with oxotremorine in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Memory impairments following basal forebrain lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Aging, memory, and the cholinergic system: a study of dichotic listening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Human Serial Learning: Enhancement with Arecholine and Choline Impairment with Scopolamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Physostigmine: Improvement of Long-Term Memory Processes in Normal Humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Brain muscarinic receptors in senile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Cortical muscarinic receptor subtypes and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profding of arecoline in treated alzheimer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Physostigmine and Recent Memory: Effects in Young and Aged Nonhuman Primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Cholinergic receptor interactions and their effects on long-term memory processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

No response to high-dose muscarinic agonist therapy in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

Cell loss from the nucleus basalis of Meynert in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990054-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(96)90054-5

1 reference

20 April 2018

1 reference

20 April 2018